PATENT CLAIM ANALYSIS

Application Number: 15763942
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-05
Patent Classification: ["514", "04400A"]

Abstract:
Disclosed herein are compositions and compounds comprising modified oligonucleotides for modulating AGT and modulating a RAAS pathway related disease, disorder and/or condition in an individual in need thereof. A RAAS pathway related disease, disorder and/or condition in an individual such as hypertension can be treated, ameliorated, delayed or prevented with the administration of antisense compounds targeted to AGT.

Claim (Index 27):
The compound of  26 , wherein the conjugate group comprises a GalNAc moiety.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 90.0
- Lexical Diversity: 1.42222
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14701999', '15562843', '14959714', '14768180', '15849017']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7720378441405457
- 35 USC 102 Novelty (BERT): 0.5452067104521272
- Combined Prediction Score: 0.7493547307717039
- Mean Citation Score: 367.957906
- Max Citation Score: 383.8001
- Similarity Product: 252.4860859813154

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test